	FORM	FOR-OGIT-058
	REPORT OF RESULTS OF THE CLINICAL TRIALS TO BE PUBLISHED IN THE REPEC	Edition No. 01

Instructions: Dear User, remember that the application must be filled out through the electronic form available in the Peruvian Registry of Clinical Trials (REPEC) at: <http://www.ensayosclinicos-repec.ins.gob.pe>

1. ADMINISTRATIVE INFORMATION


1. Name of the notifying Institution:	<i>(Automatically generated during electronic registration in REPEC)</i>		
2. Data of the person responsible for recording information.			
Last name:		Identification document:	
Mother's last name:		Telephone:	
Names:		Email:	

2. GENERAL INFORMATION

1. Title of the clinical trial: 2. Name of the investigational product:	<i>(Automatically generated during electronic registration in the REPEC)</i>		
3. Indication studied:			
4. Sponsor(s):	<i>(Automatically generated during electronic registration in the REPEC)</i>		
5. Protocol Code:	<i>(Automatically generated during electronic registration in the REPEC)</i>		
6. Clinical phase:	<i>(Automatically generated during electronic registration in the REPEC)</i>		
7. Study start date: (Global)			
8. Study completion date: <i>(Date of the last visit of the last global participant)</i>			
9. Primary Objective(s):			
10. Secondary Objective(s): 11. Study design:			
12. Number of Planned Patients: 13. Number of Patients Analyzed: 14. Main selection criteria:			
15. Dosage and method of administration of the Investigational Product:			
16. Duration of treatment:			
17. Primary assessment criteria(s): 18. Secondary assessment criteria(s): 19. Publication:			
<i>(If it is already available, enter the DOI or URL)</i>	DOI:		
	URL:		
20. Date of first publication in a scientific journal			
21. Report date:			


3. FLOW OF PARTICIPANTS


I. Name of the Study Period	
1. Recruitment	
1.1. Number of participants evaluated for selection	
1.2. Number of excluded participants	
• Number of participants who do not meet inclusion criteria	
• Number of participants who refuse participation	
• Number of participants excluded for other reasons	
1.3. Detail reasons why they were excluded.	
Reason 1.....	

	FORM	FOR-OGIT-058
	REPORT OF RESULTS OF THE CLINICAL TRIALS TO BE PUBLISHED IN THE REPEC	Edition No. 01

Reason 2.....			
Reason n.....			
1.4.Number of participants enrolled in the study			
2. Randomization			
2.1.Number of randomized participants			
2.2.Number of arms or groups of the study			
<i>Based on what was entered, complete the information requested below for each arm:</i>			
	Group 1	Group 2	Group n
2.3.Name of the arm or group			
2.4.Description of the intervention <i>(Details about the intervention [may be, for example: dose, dosage form, frequency, duration])</i>			
2.5.Number of participants assigned to the intervention			
ÿ Number of participants who received the intervention			
ÿ Number of participants who did not receive the intervention			
Detail reasons:			
Reason 1.....			
Reason 2.....			
Reason n.....			
3. Follow-up 3.1.			
Number of participants lost to follow-up			
Detail the reasons for loss to follow-up			
3.2.Number of participants interrupt the intervention			
Detail reasons for the interruption: Reason 1			
Reason 2.....			
Reason n.....			
4. Analysis			
4.1.Number of participants analyzed			
4.2.Number of participants excluded from the analysis			
4.3.Detail reasons for exclusion			
Reason 1.....			
Reason 2.....			
Reason n.....			

The following graph must be attached, if available:

	FORM	FOR-OGIT-058
	REPORT OF RESULTS OF THE CLINICAL TRIALS TO BE PUBLISHED IN THE REPEC	Edition No. 01



4. BASELINE CHARACTERISTICS


4.1. GENERAL DATA

1. Total number of participants in the Baseline	(Total number of units analyzed)
2. Number of arms or groups	(Enter number of study arms)
3. Number of variables in the baseline	


Based on what was entered, complete the information requested below for each arm:

4.2. AGE VARIABLE

4. Variable name	Age
------------------	-----


	FORM	FOR-OGIT-058
	REPORT OF RESULTS OF THE CLINICAL TRIALS TO BE PUBLISHED IN THE REPEC	Edition No. 01

5. Description of the analysis population in the Baseline <i>(If necessary, for example whether or not the pediatric population was included, age ranges for the study, etc.)</i>					
6. Total number of participants corresponding to the group (Baseline)		<i>Group 1</i>	<i>Group 2</i>	<i>Group n</i>	<i>Total</i>
AGE AS A CATEGORICAL VARIABLE					
7. Number of participants per category corresponding to the group	<input type="checkbox"/> 18 years				
	<input type="checkbox"/> 18 – 65 years				
	<input type="checkbox"/> 65 years				
8. Unit of measurement	Participants				
AGE AS A CONTINUOUS VARIABLE					
Item		<i>Group 1</i>	<i>Group 2</i>	<i>Group n</i>	<i>Total</i>
9. Summary measure <i>(Select summary measure to be used:</i> <input type="checkbox"/> Mean <input checked="" type="checkbox"/> Median <input type="checkbox"/> Least Squares <input type="checkbox"/> Mean <input type="checkbox"/> Geometric mean					
10. Dispersion measurement <i>Select dispersion measure to be used:</i> <input type="checkbox"/> Standard deviation <input type="checkbox"/> Interquartile range <input type="checkbox"/> Total range					
11. Unit of measurement					
AGE, ANOTHER CATEGORIZATION					
Item		<i>Group 1</i>	<i>Group 2</i>	<i>Group n</i>	<i>Total</i>
12. Number of participants per category corresponding to the group	Category 1 title				
	Category 2 title				
	Category title n				
13. Unit of measurement					
4.3. VARIABLE SEX					
14. Variable name		Sex			
15. Description of the analysis population in the Baseline		<i>(Complete tables only when the study included both sexes, otherwise indicate it in the description)</i>			
Item		<i>Group 1</i>	<i>Group 2</i>	<i>Group n</i>	<i>Total</i>
16. Number of participants per category corresponding to the group (Baseline)	Female				
	Masculine				
17. Unit of measurement	Participants				
4.4. OTHER CONTINUOUS VARIABLES					
<i>Enter information for each additional continuous variable</i>					
18. Variable name					
19. Description of the analysis population in the Baseline					
Item		<i>Group 1</i>	<i>Group 2</i>	<i>Group n</i>	<i>Total</i>
20. Summary measure <i>(Select summary measure to be used:</i> <input type="checkbox"/> Mean <input checked="" type="checkbox"/> Median <input type="checkbox"/> Least Squares <input type="checkbox"/> Mean					

	FORM	FOR-OGIT-058
	REPORT OF RESULTS OF THE CLINICAL TRIALS TO BE PUBLISHED IN THE REPEC	Edition No. 01

<input type="checkbox"/> Geometric mean					
21. Dispersion measurement Select dispersion measure to be used:					
<input type="checkbox"/> Standard deviation					
<input type="checkbox"/> Interquartile range					
<input type="checkbox"/> Total range					
22. Unit of measurement					
4.5. OTHER CATEGORICAL VARIABLES Enter information for each additional continuous variable					
23. Variable name					
24. Description of the analysis population in the Baseline					
Item		Group 1	Group 2	Group n	Total
25. Number of participants per category corresponding to the group.	Category 1 title				
	Category 2 title				
	Category title n				
26. Unit of measurement					

5. MEASUREMENT OF RESULTS					
5.1. ASSESSMENT CRITERIA(S)					
27. Type of evaluation criterion		<input type="checkbox"/> Primary <input type="checkbox"/> Secondary Other: <input type="checkbox"/>			
<i>A table must be generated for each assessment criterion and complete the following information:</i>					
28. Name of the evaluation criterion <i>According to evaluation criteria indicated in the protocol (outcomes)</i>					
29. Description of the endpoint <i>(Brief description of outcome measure)</i>					
30. Period of time in which the measurement was carried out <i>As stated in the protocol</i>					
31. Description of the analyzed population <i>(Type of analysis population)</i>					
32. Number of arms or groups considered for analysis					
<i>Enter information for each arm or group according to the following table (a table must be generated for each arm or group and according to each endpoint)</i>					
33. Name of primary endpoint					
34. Description of the endpoint <i>(Brief description of outcome measure)</i>					
35. Period of time in which the measurement was carried out <i>As stated in the protocol</i>					
36. Description of the analyzed population <i>(Type of analysis population)</i>					
37. Number of groups considered for analysis					
38. Title of the arm or group		Group 1	Group 2	Group n	
39. Description of the arm or group <i>(Details about the intervention [may be, for example: dose, dosage form, frequency, duration])</i>					
40. Total number of participants analyzed in the arm or group					
41. Summary measure type Select measure:		<input type="checkbox"/> Mean <input type="checkbox"/> Median <input type="checkbox"/> Least squares mean <input type="checkbox"/> Geometric mean <input type="checkbox"/>			

	FORM	FOR-OGIT-058
	REPORT OF RESULTS OF THE CLINICAL TRIALS TO BE PUBLISHED IN THE REPEC	Edition No. 01

		<input type="checkbox"/> Number <input type="checkbox"/> Percent <input type="checkbox"/> Does not apply <input type="checkbox"/> Standard deviation <input type="checkbox"/> Standard error <input type="checkbox"/> Interquartile range Total range <input type="checkbox"/> Confidence interval:% <input type="checkbox"/> Geometric variation coefficient)		
42. Dispersion/precision measurement Select measure:				
		Group 1	Group 2	Group n
43. Measurement value summary	44. Value of dispersion/precision			
45. Apply categories	Category 1 title			
	Category 2 title			
	Category title n			
46. Unit of measurement				
5.2. STATISTIC ANALYSIS				
1. Description of the statistical analysis				
2. Comparison groups				
3. Type of statistical test		<input type="checkbox"/> Superiority <input type="checkbox"/> Non-inferiority <input type="checkbox"/> Equivalence		
In case of selecting Non-inferiority or Equivalence:	Power calculation or other key information:			
	Definition of the non-inferiority margin/ equivalence margin			
4. Hypothesis Testing	p value:			
	Statistical test used:			
5. Estimation method	Measurement of effect:	For example Hazard ratio, Mean difference, Odds Ratio, Relative risk, etc.		
	Estimated value:			
	Confidence interval:	It must include the level expressed as a percentage: Eg 95%, 99% Number of queues: 1 or 2 queues Lower limit Upper limit		
	Dispersion type	<input type="checkbox"/> Standard deviation <input type="checkbox"/> standard error of the mean		
	Dispersion value			
6. Other type of statistical analysis:		Provide a description and results if statistical analysis cannot be presented using the above items.		

6. ADVERSE EVENTS										
1. Time period										
2. Description of the report of adverse events		Additional pertinent information about the collection of adverse events or how the analysis population was determined.								
3. Arm/Group Title		Group 1	Group 2	Group n						
4. Description of the Arm/Group										
6.1. SERIOUS ADVERSE EVENTS										
		Group 1			Group 2			Group n		
1. Total according to group		No. affected	No. at risk	Number of events	No. affected	No. at risk	Number of events	No. affected	No. at risk	Number of events

